Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohort

Vladimir Gainullin,[1] Mael Manesse,[1*] Fanglei Zhuang,[1] Melissa Gray,[1] Hee Jung Hwang,[1*] Gustavo C. Cerqueira,[1*] Christopher L. Nobles,[1*] Madhav Kumar,[1] Kevin Arvai,[1*] Xi Chen,[1*] Christopher C. Tyson,[1] Chen Ji,[1*] Jin Bae,[1] Violeta Beleva Guthrie,[1*] Jaspreet Kaur,[1] Viatcheslav E. Katerov,[1] Larson Hogstrom,[1*] Leonardo Hagmann,[1*] Philip J. Uren,[2] Jorge Garces,[1] Hatim T. Allawi,[1] Vuna Fa,[1*] Abigail McElhinny,[1*] Gerard A. Silvestri,[3] David Chesla,[4] Robert W. Given,[5] Tomasz M. Beer,[1] Frank Diehl[2]**

[1]Exact Sciences Corporation, Madison, WI
[2]Exact Sciences Corporation, La Jolla, CA
[3]Medical University of South Carolina, Charleston, SC
[4]Corewell Health, Grand Rapids, MI
[5]Urology of Virginia, Virginia Beach, VA
*Former employee of Exact Sciences Corporation

**Corresponding Author
Frank Diehl, PhD
Senior Vice President, Research & Development, Multi-cancer Early Detection
Exact Sciences Corporation
11085 N. Torrey Pines Rd.
La Jolla, CA 92037
Email: fdiehl@exactsciences.com

Short title Multi-cancer early detection biomarkers in plasma

Keywords Multi-cancer early detection, cell-free DNA (cfDNA), methylation, proteins, mutations, reflex assay, machine learning

Abbreviations ASCEND-2, Ascertaining Serial Cancer patients to Enable New Diagnostic 2; cfDNA, cell-free DNA; CHIP, clonal hematopoiesis of indeterminate potential; CV, cross-validation; DETECT-A, Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing; ECL, electrochemiluminescence; gDNA, genomic DNA; LQAS, Long-probe Quantitative Amplified Signal; MCED, multi-cancer early detection; MDM, methylated DNA marker; MP, methylation and protein; MP-reflex, methylation and protein plus somatic mutation reflex; PCR, polymerase chain reaction; PPRLS, privacy-preserving record linkage; QC, quality control; ROC AUC, Receiver Operating Characteristic Area Under the Curve; SEER,

41   National Cancer Institute Surveillance, Epidemiology, and End Results; SoC, standard of care;

42   TELQAS, Target Enrichment Long-probe Quantitative Amplified Signal; USPSTF, United States

43   Preventive Services Taskforce

44
Abstract 290 words

Background:

Multi-target blood tests have the potential to detect a broad range of cancer types and stages.

We previously trained and independently assessed the performance of four biomarker classes

for cancer detection in a retrospectively assembled case-control feasibility study. The primary

aim of this study was to assess the performance of a methylation and protein (MP) classifier

using samples from a large, multi-center, prospectively collected case-control study. As part of

the ongoing assay development process, we also performed an exploratory analysis

investigating the addition of a somatic mutation reflex approach (MP-reflex) on samples with

scores below the threshold for a positive MP call but above a clear negative MP call.

Methods:

This study included 6,352 samples (1,438 cancer and 4,914 non-cancer) representing all stages

among 21 tumor organ types divided approximately equally between a training and a test set.

The sensitivity of the MP classifier was determined at a high specificity. The MP-reflex approach

was investigated on MP samples at the same specificity threshold and detectable MP signals

above pre-specified lower thresholds.

Results:

At 98.5% specificity, the observed overall sensitivity for MP biomarkers was 50.9%, with

sensitivities of 15.4%, 26.1%, 38.0%, 67.8%, 85.5%, and 37.5% for stages I, I and II combined,

II, III, IV, and unknown, respectively. When breast and prostate cancers were excluded from the

analysis, overall test sensitivity was 56.8%, with sensitivities of 17.2%, 30.7%, 48.6%, 73.5%,

86.5%, and 40.0% for stages I, I and II combined, II, III, IV, and unknown, respectively.

Conclusion:

Methylation and protein biomarkers detected all cancer organ types incorporated in the analysis,

including those without standard of care (SoC) cancer screening options and aggressive

cancers with poor 5-year survival. These results demonstrate the potential clinical validity of

multi-biomarker testing for the detection of several cancer types.

72
73 **Introduction**
74
Cancer is the second leading cause of death in the U.S, with more than two million new

cancer cases and over 618,000 cancer deaths projected to occur in 2025.[1] The United States

Preventive Services Taskforce (USPSTF) recommends routine cancer screening for breast,

colorectal, and cervical cancer in average risk individuals, and for lung cancer in individuals with

elevated risk due to a pre-specified threshold exposure to tobacco.[2-5] Standard of care (SoC)

cancer screening programs have improved mortality rates for these four cancers; however, two-

thirds of annual cancer deaths are the result of cancers without endorsed screening.[1, 6]

Multi-cancer early detection (MCED) testing has the potential for earlier detection of

multiple cancers simultaneously, including lower prevalence cancers and aggressive cancers

(i.e. pancreatic, esophageal, liver, stomach, and ovarian) that are often detected at later

stages.[1, 6] Advances in molecular and computational technologies have enabled the sensitive

and specific detection of tumor-derived biomarkers in the blood. Most MCED assays currently in

development utilize single biomarker classes, such as cell-free DNA (cfDNA) hyper-

methylation,[7-14] mutations,[15] fragmentation patterns,[16-20] or proteins[21] to detect cancers.

However, the utilization of single biomarker types may not account for the complexity and

heterogeneity of cancer, particularly when tasked with detecting multiple cancers by a single

test.[22] A combined, multi-target approach provides a more comprehensive assessment of

shared cancer-associated biomarkers present in the blood, with the goal of improved sensitivity

for early cancer detection.[23] To that end, MCED tests incorporating multi-biomarker classes are

also in development, utilizing DNA fragmentation and methylation with or without protein

markers, or cfDNA mutation, aneuploidy, and methylation biomarkers, together with cancer-

associated protein quantification.[24-29]

CancerSEEK was a multi-target MCED assay developed in a case-control setting and

examined in a large prospective study and served as the foundation for subsequent test

development. CancerSEEK (mutations and select proteins) was utilized in the Detecting

cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A)

study; the first prospective interventional clinical study to evaluate an MCED blood test. In

DETECT-A, CancerSEEK detected 19% of stage I cancers, 15% of stage II cancers and 30% of

stage III cancers at a specificity of 99%.[27] Using another initial version of CancerSEEK

(mutations, proteins, and a machine learning classifier), Cohen et al., reported a sensitivity of

70% and a specificity of over 99% for eight types of cancer (ovary, liver, stomach, pancreas,

esophagus, colorectal, lung, or breast) in a case-control feasibility study of 1005 patients.[24]

Douville *et al.* hypothesized that the test performance observed in the Cohen study could

be improved by the addition of aneuploidy to the biomarker panel.[30] While maintaining a specificity

of 99%, the combination of aneuploidy, cfDNA mutations, proteins, and a machine learning

classifier detected seven cancer types (liver, ovary, pancreas, esophagus, stomach, colorectal,

and lung); the sensitivity ranged from 77 to 97% and 38% for breast cancer. Using retrospectively

assembled case-control feasibility study data, our group has also assessed MCED test

performance utilizing DNA methylation and protein combinations,[31, 32] as well as 3-biomarker

classes (methylation, aneuploidy, and proteins) and 4-biomarker classes (methylation, mutations,

aneuploidy, and proteins) with a machine learning classifier.[25, 26] The aim of this study was to

assess the performance of a two-biomarker (methylation and protein, MP) MCED assay using

samples from a large, multi-center, prospectively collected case-control study. Aneuploidy was

tested, but we did not include a performance assessment in this study (unpublished data). We

also assessed the performance of a somatic mutation reflex approach in samples with initially

negative MP-results (MP-reflex) to test the feasibility of an MP-reflex assay in a high-throughput,

reduced cost setting. We hypothesized that MP-reflex might be an efficient strategy to add a third

biomarker class and enhance sensitivity for the detection of early-stage cancer.

123
Methods

Study Participants and Sample Collections

Ascertaining Serial Cancer patients to Enable New Diagnostic 2 (ASCEND-2), a multi-center,

prospectively collected case-control study of clinically characterized participants, was the main

source of the samples for this classifier development study. One hundred ninety sites within the

United States (35 states) and 15 sites within Europe were engaged for subject enrollment.

ASCEND-2 study included male and female subjects ≥50 years old with known cancer,

suspicion of cancer, and controls without suspicion of cancer. Cancer cases had untreated

primary malignancies confirmed through pathology reports and/or clinical/radiographic data.

Subjects were excluded from the study if they had any previous cancer diagnosis within the past

5 years (with the exceptions of basal cell or squamous cell skin cancers), or cancer recurrence

within the study timeframe, or a concurrent diagnosis of multiple primary cancers. While free

from suspicion of cancer at the time of enrollment, controls were not required to have completed

all recommended cancer screening tests and were not followed contributing a blood sample to

confirm the absence of cancer. All collection sites had Institutional Review Board approval, and

all eligible subjects provided written informed consent and were assessed for study participation

eligibility. Over 25,900 participants were enrolled in ASCEND-2, which included over 5,900

known cancer cases. A subset of these samples was selected to develop two different MCED

cancer classifiers. Samples were selected based on plasma volume availability, clinical eligibility

criteria, availability of validated clinical data prior to laboratory testing initiation, and

demographic matching requirements between the training and test set cohorts. The number of

cancers per organ site was targeted to represent cancers with high, common, and rare

incidence compared to adjusted National Cancer Institute Surveillance, Epidemiology, and End

Results (SEER) cancer incidence (accessed March 2024).[6] The number of cancers per stage

was targeted to be equal and not represent SEER to allow for data generation across all stages.

In order to meet these sample selection targets the ASCEND-2 enrollment was supplemented

with a set of 187 samples from a commercial vendor (Audubon Bioscience, Houston TX), and

12 cancer samples from an Exact Sciences study, Specimen Collection Study to Evaluate

Biomarkers (2021-05). Blood was collected in LBgard® tubes for plasma and buffy coat

extraction.

Methylated DNA Marker (MDM) Analysis

MDM candidates were identified from a genome-wide discovery approach using reduced

representation bisulfite sequencing of DNA extracted from frozen primary cancer tissues and

control tissues, in addition to normal buffy coat control samples. Candidate regions were

selected where there was differential hypermethylation between the cases and controls. MDM

candidates were then confirmed biologically on independent tissues before being tested on

archived plasma. The results of these marker selection and elimination studies were designed

primarily to remove non-discriminating biomarkers. Only the top performing MDMs across the

many different cancer studies were chosen for further evaluation as candidate methylation

markers for blood-based detection of cancer.[31, 33]

cfDNA was extracted from 6 mL plasma followed by bisulfite conversion on a Hamilton

Microlab STARlet (Hamilton Robotics, Reno, NV) using reagents manufactured by Exact

Sciences Corporation (Madison, WI). Bisulfite converted cfDNA was then analyzed using Target

Enrichment Long-probe Quantitative Amplified Signal (TELQAS™) chemistry.[31, 33] For the initial

target enrichment, converted cfDNA was transferred to a 96-well polymerase chain reaction

(PCR) plate and subjected to a multiplex PCR to amplify the MDMs and a reference methylation

marker. The PCR products were diluted 10-fold and evaluated in triplex or biplex assays using

Long-probe Quantitative Amplified Signal (LQAS[TM]) on a Quantstudio 5 Dx Real-Time PCR

Instrument (Life Technologies Corporation, Grand Island, NY). TELQAS combines amplification

using real-time PCR and allele-specific detection of methylated target DNA through an invasive

cleavage assay.

Protein Analysis

Plasma protein concentrations were measured using commercially available assays for

select proteins on a Roche cobas e801 instrument (Roche Diagnostics, Indianapolis, IN) per

manufacturer recommendations.[33] The cobas e801 analyzer uses electrochemiluminescence

(ECL)-based immunoassays to measure protein concentrations.

182
Mutation Analysis

Select mutations (i.e. somatic variants associated with cancer) were assessed by

extracting cfDNA from ~10 mL of plasma followed by sequencing using a modified version of a

technology described by Cohen et al. 2021.[34] Genomic DNA (gDNA), extracted from the

matched buffy coat, was used for sequencing regions that were positive for mutations in cfDNA

to verify whether the detected mutations were attributable to clonal hematopoiesis of

indeterminate potential (CHIP). Only mutations detected in plasma but absent in the matched

buffy coat samples were considered tumor derived variants. Samples were subjected to quality

control (QC) based on sample-level, run-level, and control-level metrics. Sample counts and QC

failure modes were recorded. The MP and MP-reflex testing workflow is shown in Figure 2.

Machine learning model development

MP classifier development

Separate plasma aliquots were tested with the protein and methylation assays as

illustrated in Figure 2. Prior to classifier training, samples were partitioned into training (cross-

validation (CV), mini-hold-out) and test (hold-out test) sets (Figure 1). Only samples that passed

pre-specified methylation and protein assay quality control criteria were included in the training

process. The training set was used to select model architecture, feature engineering, and

transformation approaches as well as to perform hyperparameter tuning, and calibration of

specificity thresholds. MP classifier threshold calibration was performed on the CV set, with the

aim of achieving greater than or equal to 99.0% specificity while maintaining high sensitivity

within a mini-hold-out set (223 cancers; 985 non-cancers).

Machine learning was used to develop and train two individual binary (cancer or non-

cancer) classifiers for the methylation and protein panels, respectively (Figure 3a). The overall

methodology was as follows: 5-fold stratified CV partitions were generated using age bin (half-

decade), gender, ethnicity, race, cancer organ and stage as strata with the aim to produce

proportional train/validate partitions across folds. These static partitions were then used to

perform model selection across common linear and non-linear estimator architectures. Model

bias estimation was evaluated in comparison between train/validation performance using

sensitivity, specificity, total and partial Receiver Operating Characteristic Area Under the Curve

(ROC AUC) results. Model architecture with the least bias and highest performance was further

refined with hyper-parameter tuning and validation curve assessment. Robust model

parameters and thresholds were then locked before final model performance assessment using

the independent held-out test set.

After classifier development was completed, the individual methylation and protein

classifier results (cancer or non-cancer calls) were combined by an OR-logic overarching

classifier to generate the final classification status (positive or negative). OR-logic was selected

as the overarching MP classifier; other approaches (early and late fusion, weighted voting, and

logistic regression) did not offer significant advantages. The result was deemed positive when

either the methylation or protein assay provided a cancer-positive call. Hold-out test set samples

were evaluated using this final overarching OR-logic classifier configuration (Figure 3a).

MP-reflex classifier development

All samples were analyzed using the combined MP classifier described above. The MP-

reflex classifier training included 20 organ sites and all stages of cancer. Mutation classifier

thresholds were tuned using optimization in cross-validation within the training data set.

Samples were tested following the mutation assay workflow using plasma as well as the

corresponding buffy aliquots. The schematic of the different cancer classifiers that were

developed and tested is shown in Figure 3.

The mutation classifier consisted of three main components: variant-level artifact score,

CHIP, and sample-level aggregate mutation score that weighed evidence from variants passing

artifact and CHIP filter. The three components were developed using an independent sample

collection. The MP classifier was adapted to determine three outcomes (three-zone partitioning):

high-confidence cancer positive (red), high-confidence cancer negative (green), and signal that

fell between these two categories or zones (yellow; middle) (Figure 3b). Samples with high-

confidence scores were classified as cancer or non-cancer calls, respectively. Samples with MP

results that fell between high-confidence positive or high-confidence negative results (e.g.,

middle zone) underwent a follow up mutation assay evaluation. An OR logic model was chosen

as the overarching MP classifier.

For MP-reflex classifier training, mutation samples that failed QC and were in the middle

zone were considered negative (no variants) to avoid biasing the MP-reflex training results from

multiple mutation configuration versions to MP. MP and MP-reflex thresholds were calculated

using ROC curves in stratified cross-validation. Optimal thresholds across validation folds were

averaged, locked before testing and used for final performance estimation. The resulting

mutation classifier differentiated the outcome into a binary cancer or non-cancer call.

Statistical analysis

Sensitivity, specificity and binary classification thresholds were calculated using scikit-

learn metrics. 95% confidence intervals were calculated using binomial proportion Wilson score

method (statsmodels).

Results

Participants and Sample Characteristics

A total of 6,352 samples were selected from the ASCEND-2 study as well as two other

collections to develop and test a MP (Figure 1) as well as an MP-reflex cancer classifier (Figure

5). This overall set included 1,438 cancer participants across 21 organ sites and stages (anus

(n=28), bladder and urinary (n=65), breast (n=165), cervix uteri (n=22), colon and rectum

(n=161), esophagus (n=53), head and neck (squamous cell) (n=78), uterine (n=81), kidney

(n=80), lung and bronchus (n=348), pancreatic (n=76), prostate (n=66), small intestine (n=12),

liver and bile duct (n=50), stomach (n=58), ovary (n=37), thyroid (n=25), vulva (n=21), testis

(n=2), and hematologic malignancies (non-Hodgkin lymphoma (NHL; n=9) and multiple

myeloma; n=1) (Supplementary Materials Table 1). Non-cancer and cancer participants were

similar for age, sex, and race/ethnicity distributions (Table 1). The study recruited participants

that were broadly representative of the US population, with 81.7%, 13.0%, 12.9%, and 3.2%,

identifying as White, Hispanic/Latino, Black/African American, and Asian, respectively.

Specifically, based on the 2020 U.S. census rates and the FDA's 2020 clinical trial participation

rates,[35, 36] the Black/African American population was slightly overrepresented in both the

training and testing cohorts. The Hispanic/Latino ethnicity rate exceeded the clinical trial

participation rate; whereas the representation rate for Asian participants was slightly lower than

both the 2020 U.S. census and FDA 2020 clinical trial participation rates. Overall, the

race/ethnicity participation rates aligned with expectations for a classifier development study.

Cancer stages and organ sites in the training and test sets collectively represent more

than 80% of incident cancers observed in the general population.[1] The number of cancers per

organ site was targeted to represent cancers with high, common, and rare incidence compared

to adjusted SEER cancer incidence (accessed March 2024),[6] lung and bronchus cancers were

over-represented (SEER: 15.8% vs. 24.2% for ASCEND-2), while breast (17.7% vs. 11.5%),

prostate (17.5% vs. 4.6%), and hematological cancers were under-represented. The cancers

used for the classifier development by cancer organ type as shown in Supplementary Table 1.

Participant demographics for the analyzable MP training and test sets are shown in

Supplementary Table 2. Overall, cancer stage distributions within organ sites were

approximately equal for stages I-IV (27%, 21%, 26%, and 22% respectively) and ~3% with

unknown stage (Supplementary Figure 1).

Methylation-Protein (MP) classifier training and testing

MP classifier interrogation

The generalizability of the MP classifier was evaluated by comparing the performance of

the full training set (including the CV set and mini-hold-out set), the CV set alone, and the test

set. The full training set (n=3,027) and 5-fold cross-validation set (n=1,819) achieved 98.9%

(95% CI: 98.1-99.3%) and 98.8% (95% CI: 98.3-99.2%) specificity, respectively. The test set

(n=3,163) achieved 98.5% specificity (95% CI: 97.9-98.9%), with a false positive rate of 1.5%

(37/2432 non-cancer cases). No significant bias was observed between the full training set, CV

set, and test set performance by stage (Supplementary Figure 2) or specific tumor organ site

(Supplementary Figure 3).

MP classifier test set performance

The test set included 780 cancers and 2,534 non-cancers that were all tested using the

methylation and protein assays. A total of 28 (0.8%) samples failed pre-specified assay quality

control criteria. Fifty-seven samples from participants over 84 years of age (outside of the

intended use age range) were removed from the test set analysis. A 72-hour blood processing

window requirement was also applied to the test set cohort that resulted in the exclusion of an

additional 67 cases. MP classifier test set performance without age and blood processing

exclusions is shown in Supplementary Table 5. The set without these exclusions demonstrated

an overall sensitivity of 51.6% (95% CI: 48.0-55.1%) at a specificity of 98.4% (95% CI: 97.9-

98.9%).

The remaining analyzable MP sample set was 729 cancers and 2,434 non-cancers. The

MP classifier demonstrated an overall sensitivity of 50.9% (95% CI: 47.3-54.5%), and

sensitivities of 15.4% (95% CI: 10.9-21.3%), 26.1% (95% CI: 21.7-31.0%), 38.0% (95% CI:

30.9-45.7%), 67.8% (95% CI: 60.6-74.2%), 85.5% (95% CI: 79.4-90.0%) and 37.5% (95% CI:

22.9-54.7%) for stages I, I and II combined, II, III, IV, and unknown, respectively for 21 organ

types (Table 2). MP classifier performance was also assessed with breast and prostate cancers

excluded, with an observed overall sensitivity of 56.8% (95% CI: 52.8-60.7%), and sensitivities

of 17.2% (95% CI: 12.0-24.2%), 30.7% (95% CI: 25.4-36.6%), 48.6% (95% CI: 39.4-57.9%),

73.5% (95% CI: 66.0-79.9%), 86.5% (95% CI: 80.2-91.0%), and 40.0% (95% CI: 24.6-57.7%)

for stages I, I and II combined, II, III, IV, and unknown, respectively. Overall sensitivity excluding

cancer organ types with average-risk SoC screening (i.e. excluding breast, prostate, cervix

uteri, colon and rectum) was 54.8% (95% CI: 50.4-59.2%) and 63.7% (95% CI: 58.0-69.0%) for

the six most aggressive cancer organ types with the shortest 5-year survival rate[1] (i.e. pancreas,

esophagus, liver, lung and bronchus, stomach, and ovary). MP organ-specific performance

ranged from 11.8% (95% CI: 5.5-23.4%) for prostate to 80.0% (95% CI: 60.9-91.1%) for liver

and bile duct sites (Figure 4) and Table 3. Stage distributions for each organ type are provided

in Supplementary Table 3.

MP test set performance from all enrollment sites was also compared to the

performance from sites that were unique in the test set to determine if collection site influenced

the classifier performance. Thirty-one percent of test set samples (non-cancers n=597; cancers

n=383) were obtained from unique collection sites (n=71 sites) that were not included in the

training set. The observed unique test set collection site overall sensitivity of 56.7% (95% CI:

51.7-61.5%) and 99.3% (95% CI: 98.3-99.7%) specificity were similar to the overall sensitivity

and specificity observed for the full test set (sensitivity: 50.9% (95% CI: 47.3-54.5%); specificity

98.5% (95% CI: 97.9-98.9). Performance by stage was also similar between these test set

cohorts (Supplementary Figure 4).

Methylation Protein (MP)- reflex classifier training and testing

MP-reflex classifier training

6,352 samples (1,438 cancers; 4,914 non-cancers) were utilized for the MP-reflex

classifier development and testing as outlined in Figure 5. Participant demographic information

for the analyzable MP-reflex classifier training and test sets is shown in Supplementary Table 4.

Of the 3,038 samples pre-assigned to the training set, 3,027 analyzable samples (654 cancers;

2,373 non-cancers) were used to train the MP classifier as outlined above as well as for setting

the lower bound classification between high-confidence negative and samples with middle zone

results. The mutation classifier was trained on a subset of 931 (416 cancers and 515 non-

cancers).

MP-reflex classifier test set performance

3,223 analyzable samples (746 cancers; 2,477 non-cancers) representing 20 organ

types (stomach, ovary, prostate, colon and rectum, lung and bronchus, bladder and urinary,

breast, head and neck (squamous cell), kidney, pancreas, uterus, esophagus, anus, vulva, liver

and bile duct, small intestine, thyroid, cervix uteri, testis, Non-Hodgkin Lymphoma) and all

stages were used to test the MP-reflex classifier (Figure 5). Multiple Myeloma was excluded

from the analysis due to a small sample number (n=1). MP classifier resulted in 462 (299

cancers; 163 non-cancers) samples that fell into a "middle zone" (i.e., MP classifier results that

fell in-between confident positive and confident negative calls), and these samples were

analyzed using the mutations classifier.

By applying the tuned mutations thresholds, the MP-reflex classifier demonstrated a

specificity of 98.5% (95% CI: 97.9-98.9%), with an overall sensitivity of 55.2% (95% CI: 51.6-

58.8%), and sensitivities of 19.0% (95% CI: 14.0-25.3%), 29.5% (95% CI: 25.0-34.5%), 41.2%

(95% CI: 34.0-48.8%), 71.9% (95% CI: 65.0-77.9%), 89.4% (95% CI: 84.1-93.1%) and 46.9%

(95% CI: 30.9-63.6%) for stages I, I and II combined, II, III, IV, and unknown, respectively for all

20 organ types. The MP-reflex classifier performance was also assessed with breast and

prostate cancers excluded, with an observed overall sensitivity of 61.6% (95% CI: 57.6-65.3%),

and sensitivities of 21.9% (95% CI: 16.0-29.3%), 35.2% (95% CI: 29.6-41.2%), 52.7% (95% CI:

43.5-61.8%), 75.9% (95% CI: 68.7-81.9%), 90.8% (95% CI: 85.4-94.3%) and 51.7% (95% CI:

34.4-68.6%) for stages I, I and II combined, II, III, IV, and unknown, respectively. Overall

sensitivity excluding cancer organ types with average-risk SoC screening (i.e. excluding

breast, prostate, cervix, colon and rectum) was 59.9% (95% CI: 55.1-63.6%) and 66.9% (95%

CI: 61.4-71.9%) for the six most aggressive cancer organ types with the shortest 5-year

survival rate[1] (i.e. pancreas, esophagus, liver, lung and bronchus, stomach, and ovary) (Table

4).

MP and MP-reflex classifier performance comparison

MP and MP-reflex classifier performance were compared using the MP-reflex test set

(746 cancers and 2,477 non-cancers). At specificities of ≥98.5%, the MP-reflex classifier

showed absolute sensitivity (absolute change%=MP-reflex sensitivity% minus MP sensitivity%)

increases of 3.8%, 3.1%, 2.4%, 1.1%, and 2.7%, for stages I, I and II combined, II, III, and IV,

respectively, compared to the MP classifier. The overall absolute sensitivity gain of the MP-

reflex classifier was 2.8% (5.3% relative gain; defined as MP-reflex sensitivity% minus MP

sensitivity% divided by MP sensitivity% x 100) compared to the MP classifier sensitivity.

Notably, the absolute sensitivity gain of the MP-reflex classifier for early stages (stages I and II)

was 3.1% (11.7% relative gain) compared to the MP classifier (Figure 6). The relative gain in

sensitivity was greatest in stage I disease at 25.0%.

MP and MP-reflex classifier performance was also compared for cancer organ types with

average-risk standard of care screening (i.e., excluding breast, prostate, cervix, colon and

rectum). The 59.4% (95% CI: 55.1-63.6%) observed overall sensitivity for the MP-reflex

classifier represents a 2.8% absolute increase compared to the MP classifier (56.6%, 95% CI:

52.3-60.9%). Additionally, the 66.9% (95% CI: 61.4-71.9%) overall sensitivity observed for the

MP-reflex classifier represents a 2.0% absolute increase for the six most aggressive cancer

organ types (pancreatic, esophagus, liver, lung, stomach, and ovarian) compared to the MP

classifier (64.9%, 95% CI: 59.5-70.1%). The relative sensitivity gain was 23.0% for stage I and

4.6% for stage II in this subgroup.

Discussion

Building upon our previous efforts in MCED assay development, we evaluated the

performance of two different multi-target biomarker configurations in a large, multi-center

prospectively collected case-control study. The ASCEND-2 study included a racially, ethnically,

and geographically diverse sample representative of the U.S. population.[35] Age, sex, and

race/ethnicity were comparable between the cancer and non-cancer groups in both the training

and test sets. Organ sites and cancer stages (which were approximately equally distributed)

collectively represent most incident cancers observed in the U.S. population, including

aggressive cancers and cancers without guideline-recommended screening options.

We have previously reported case-control study feasibility data for three (methylation, protein,

aneuploidy) and four biomarker classes (methylation, protein, aneuploidy, and mutations)

MCED assay configurations across fifteen organ sites. In this early detection biomarker

feasibility work, the observed overall sensitivities were 53.4% and 61.0% at specificities of

98.8% and 98.2% for the combined three or four biomarker classes, respectively.[25] We then

refined and optimized each biomarker algorithm as well as the overarching cancer classifier,

resulting in improved overall sensitivities of 55.2% and 62.4% at specificities of 99.0% and

98.0% for the combined three or four biomarker classes, respectively.[26]

Based on individual biomarker contributions to overall performance, in this study we

initially focused on a combined MP assay configuration in an ongoing effort to increase assay

efficiency while maintaining sensitivity and specificity. The MP assay classifier demonstrated an

overall sensitivity of 50.9%, which was comparable to the overall sensitivities reported above for

the three biomarkers (methylation, protein, aneuploidy) MCED assay configuration while

maintaining a high specificity of 98.5%. Measuring cfDNA-based biomarkers for breast and

prostate cancers is particularly challenging due to nominal circulating tumor DNA shedding

rates associated with low tumor burden and high variability in circulating tumor DNA due to

tumor heterogeneity.[37-39] Further, these two cancers have established high-performing

screening options. The overall sensitivity of MP performance with breast and prostate cancers

excluded was 56.8%.

MCED tests currently in development are intended to complement, not replace, SoC

cancer screening modalities. Interestingly, when cancer organ types with average-risk SoC

screening were excluded except for lung cancers, which do not have a screening option for the

general population (i.e., excluding breast, prostate, cervix, colon and rectum), the MP classifier

demonstrated an overall sensitivity of almost 55%. In addition, overall sensitivity was nearly

64% for the six most aggressive cancer types with the shortest 5-year survival. Although

preliminary, these data suggest that MCED tests may broaden population wide screening

availability for individuals who are not adherent with current screening programs and for those

with cancers without SoC screening options.

To further enhance cancer detection, particularly for stage I and II cancers, without

substantially increasing testing complexity and cost, a second three-biomarker class approach

was also explored. In this approach, methylation and protein testing are performed on all

samples first followed by mutation testing for a fraction of samples that were neither highly

positive nor negative for the methylation and protein biomarkers. By interrogating the mutation

profiles of tumor hotspots for MP "middle zone" samples, the MP-reflex approach demonstrated

a sensitivity increase of 3.1% (11.7% relative gain) for stage I and II cancers while maintaining a

specificity of 98.5%. The greatest relative improvement in sensitivity was observed for the

detection of stage I cancers. While we achieved modest improvements for stage I and II

detection with the reflex approach; early-stage sensitivities were lower than those observed for

recommended single cancer screening tests that directly interrogate the organ of interest at

lower specificities. Sensitivity improvements were also observed when cancer types with

average risk SoC screening were considered (2.8% absolute increase for MP-reflex, data not

shown) and for the six most aggressive cancer types (3.0% absolute increase for MP-reflex).

In addition to the enhanced performance exhibited by the MP-reflex classifier for early-

stage cancer detection, the reflex methodology is also more cost-effective compared to

conducting methylation, protein, and mutation testing simultaneously on all samples. The MP

classifier result triggered the reflex mutations testing in about 16% of the test set samples ,

achieving a favorable balance between improved early-stage sensitivity and reduced assay

cost. Reduction in assay cost is critical to support the ability to deliver a widely accessible assay

for all those who might benefit from MCED screening.

Limitations

Case-control studies like ASCEND-2 are an efficient data source for classifier training

and assessing classifier performance in an independent hold-out test cohort. As with any case-

control study, the approach applied here has limitations. First, ASCEND-2 enrollment

criteria for the non-cancer control cohort depended on self-reported and recorded information to

define cancer-free status just prior to or at the time of enrollment. Full adherence with

recommended cancer screening was not required. Also, ASCEND-2 did not have a pre-defined

built in longitudinal follow up included that would allow us to identify any cancer that developed

within a one-to-two-year timeframe from the time of the blood draw. Therefore, the training and

test cohorts likely included unobserved cancer or pre-cancers that could have resulted in a

cancer-related biomarker signal. Approximately 1% of individuals above the age of 50 (almost

1.8 million individuals estimated in 2025) are diagnosed with cancer each year.[40] Thus,

undiagnosed cancers are expected in the general population. For screening tests with a high

specificity that aim for no more than 1.5% false positive results, this level of undiagnosed cancer

burden represents a challenge. This would have complicated the training process as well as the

interpretation of the testing results. One approach in the future is to further evaluate these

results by utilization of privacy-preserving record linkage (PPRLS) techniques (i.e., tokenization)

to determine subsequent cancer status by linking participant data sets from electronic medical

records with results from the non-cancer test cohort.

Second, the enrollment of cancer participants in ASCEND-2 was not limited to a single

diagnostic pathway that would be reflective of an asymptomatic screening test user. Specifically,

the ASCEND-2 cancer cohort participants were identified by one of these mechanisms:

screening, incidental findings, or by symptoms. It is expected, depending on this diagnostic

enrollment mechanism, that there are differences in biomarker signal strength and distribution.

Depending on the cancer type and stage, the ratio between these three pathways could

fluctuate and may not reflect the diagnostic pathways in a screening setting.

ASCEND-2 study enrollment was enriched for lung and bronchus cancer, while breast,

prostate, and hematological cancers were under-represented. This may have influenced

performance results as sensitivities vary widely across individual cancer types. Disproportionate

over-sampling of specific cancer types with higher sensitivities (lung and bronchus) while under

sampling those with lower sensitivities (breast, prostate) would be expected to result in higher

overall sensitivities. In addition, we targeted equal stage distribution across all the cancer types

included in ASCEND-2. Consequently, compared to SEER incidence, a higher number of later-

stage cancers were included in the study.

Third, the prospectively collected ASCEND-2 included a diverse population; however,

the analyses were performed in a case-control fashion without the return of results to

participants. Reported MCED test sensitivities have been higher for case–control studies

(70.0% overall sensitivity for Cohen's CancerSEEK case–control study) compared to

prospective studies (27.1% overall sensitivity) observed in DETECT-A.[24, 27] Prospective clinical

validation studies in average risk individuals will reflect assay and clinical diagnostic work-up

performance in the intended-use population.

Finally, reporting of test performance in subsets of the study population defined by age,

gender, race, ethnicity, risk factors for cancer and other factors of interest is beyond the scope

of this report owing the small sample size available for such analyses. Future research will be

needed to further evaluate test performance in subsets of the overall population.

Conclusion

MP and MP-reflex classifier strategies resulted in overall sensitivities of 50.9% and

55.2% for a broad range of cancers respectively, at a specificity of 98.5%. These results

represent a progress report from an ongoing program developing a multi-biomarker class MCED

test.

A real-world evidence registry, Falcon (Clinical Trial Identifier: NCT06589310) was

initiated in 2024 to prospectively investigate test performance and the uptake, diagnostic

journey, adherence with guideline-recommended cancer screening, outcomes, and

psychological impacts of MCED testing.

Acknowledgements

The authors would like to thank the following individuals: Jing Tong, Amira Best, David

Sims, Jeremy Thorpe, Christopher Gault, Farhad Hatami and Mark Evans for feedback on study

design and execution, sample processing and data preparation, Natsuyo Aoyama for project

management support, Fikrullah Kisa, Peter Ngam, Jerry Machado and Raja Kakuturu for wet

laboratory leadership, Amy Lehman for statistical analysis and Amin Mazloom (Exact Sciences

Corporation, Madison, WI) for leadership and feedback. Carolyn Hall and Feyza Sancar (Exact

Sciences Corporation, Madison, WI) provided manuscript writing and editorial support. The

authors would also like to thank the patients who generously participated in the original sample

collection studies and the principal investigators and institutions who oversaw their enrollment.

Author Contributions

Conceptualization: Frank Diehl

Methodology: Vladimir Gainullin, Frank Diehl

Formal Analysis: Vladimir Gainullin, Mael Manesse, Fanglei Zhuang, Melissa Gray, Hee Jung

Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Madhav Kumar, Kevin Arvai, Xi Chen,

Christopher Tyson, Chen Ji, Jin Bae, Violeta Beleva Guthrie, Jaspreet Kaur, Viatcheslav E.

Katerov, Larson Hogstrom, Leonardo Hagmann, Philip J. Uren, Vuna Fa, Abigail McElhinny

Investigation: Gerard Silvestri, David Chesla, Robert Given

Writing-Original Draft: Vladimir Gainullin, Frank Diehl, Tomasz M. Beer

Writing-Review and Editing: Vladimir Gainullin, Mael Manesse, Fanglei Zhuang, Melissa Gray,

Hee Jung Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Madhav, Kumar, Kevin Arvai,

Xi Chen, Chris Tyson, Chen Ji, Jin Bae, Violeta Beleva Guthrie, Jaspreet Kaur, Viatcheslav E.

Katerov, Larson Hogstrom, Leonardo Hagmann, Philip Uren, Jorge Garces, Hatim T. Allawi,

Vuna Fa, Abigail McElhinny, Gerard Silvestri, David Chesla, Robert Given, Tomasz M. Beer,

Frank Diehl

Project Administration: Jorge Garces, Hatim T. Allawi, Tomasz M. Beer, Frank Diehl

Funding

This work was funded by Exact Sciences Corporation.

Disclosures

Mael Manesse, Hee Jung Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Kevin
Arvai, Xi Chen, Chen Ji, Violeta Beleva Guthrie, Larson Hogstrom, Leonardo Hagmann,
Vuna Fa, and **Abigail McElhinny** were employed at Exact Sciences Corporation at the time of
study execution and report stock ownership at Exact Sciences Corporation. **Mael Manesse**
reports employment at Nomic Bio; and stock ownership at Ultivue Inc. **Hee Jung Hwang** reports
employment at Quest Diagnostics. **Gustavo C. Cerqueira** reports employment and stock
ownership at NeoGenomics. **Christopher L. Nobles** and **Violeta Beleva Guthrie** report
employment and stock ownership at Natera Inc; and advisory/consulting roles at AOA Dx.
Christopher L. Nobles reports an advisory/consulting role at Universal Diagnostics. **Larson**
Hogstrom reports employment and stock ownership at Merck. **Vuna Fa** reports employment at
AOA Dx. **Abigail McElhinny** reports a former leadership role at Exact Sciences Corporation;
and employment, leadership, and stock ownership at AOA Dx.

Vladimir Gainullin, **Fanglei Zhuang**, **Melissa Gray**, **Madhav Kumar**, **Christopher C.Tyson**,
Jin Bae, **Jaspreet Kaur**, **Viatcheslav E. Katerov**, **Philip J. Uren**, **Jorge Garces**, **Hatim T.**
Allawi, **Tomasz M. Beer**, and **Frank Diehl** are employees at Exact Sciences Corporation and
report stock ownership at Exact Sciences Corporation. **Jorge Garces**, **Hatim T. Allawi**,
Tomasz M. Beer, and **Frank Diehl** hold leadership roles at Exact Sciences Corporation. **Philip**
J. Uren reports stock ownership at Biora Therapeutics. **Jin Bae** reports royalty interests from
Pacific Bioscience managed by The Broad Institute. **Tomasz M. Beer** reports stock ownership
at Osteologic and Osheru; and a consulting/advisory role at AstraZeneca. **Gerard A. Silvestri**
reports advisory board service at Candel Therapeutics; consulting fees from Freenome and
Biodesix; and research funding (Institutional) from NIH (RO1 screening in frail populations),
Nucleix, Inc, Biodesix, Delfi Diagnostics, and Freenome. **Gerard A. Silvestri** serves on the
American Cancer Society roundtable steering committee. **David Chesla** reports no conflict of
interest. **Robert W. Given** reports speakers' bureau service at Bayer, and Johnson & Johnson;
research funding from Francis Medical, MDX Health, Levee, and Dendreon; and travel
reimbursement from Francis Medical.

References

Siegel RL, Kratzer TB, Giaquinto AN et al. Cancer statistics, 2025. CA Cancer J Clin 2025; 75 (1): 10-45.

Curry SJ, Krist AH, Owens DK et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320 (7): 674-686.

Davidson KW, Barry MJ, Mangione CM et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19): 1965-1977.

Potter AL, Bajaj SS, Yang CJ. The 2021 USPSTF lung cancer screening guidelines: a new frontier. Lancet Respir Med 2021; 9 (7): 689-691.

Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164 (4): 279-296.

SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute (2023).[Accessed March 4, 2024].https://seer.cancer.gov/statistics-network/explorer/

Chen X, Dong Z, Hubbell E et al. Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clinical Cancer Research 2021; 27 (15): 4221-4229.

Chen X, Gole J, Gore A et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun 2020; 11 (1): 3475.

Gao Q, Lin YP, Li BS et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Ann Oncol 2023; 34 (5): 486-495.

Kandimalla R, Xu J, Link A et al. EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. Clin Cancer Res 2021; 27 (22): 6135-6144.

11 Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based

multi-cancer early detection test using an independent validation set. Ann Oncol 2021;

32 (9): 1167-1177.

12 Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and

localization using methylation signatures in cell-free DNA. Ann Oncol 2020; 31 (6): 745-

759.

13 Schrag D, Beer TM, McDonnell CH, 3rd et al. Blood-based tests for multicancer early

detection (PATHFINDER): a prospective cohort study. Lancet 2023; 402 (10409): 1251-

1260.

14 Shen SY, Singhania R, Fehringer G et al. Sensitive tumour detection and classification

using plasma cell-free DNA methylomes. Nature 2018; 563 (7732): 579-583.

15 Ris F, Hellan M, Douissard J et al. Blood-Based Multi-Cancer Detection Using a Novel

Variant Calling Assay (DEEPGEN(TM)): Early Clinical Results. Cancers (Basel) 2021;

13 (16): 4104.

16 Bao H, Wang Z, Ma X et al. Letter to the Editor: An ultra-sensitive assay using cell-free

DNA fragmentomics for multi-cancer early detection. Mol Cancer 2022; 21 (1): 129.

17 Cristiano S, Leal A, Phallen J et al. Genome-wide cell-free DNA fragmentation in

patients with cancer. Nature 2019; 570 (7761): 385-389.

18 Helzer KT, Sharifi MN, Sperger JM et al. Fragmentomic analysis of circulating tumor

DNA-targeted cancer panels. Ann Oncol 2023; 34 (9): 813-825.

19 Zhou X, Zheng H, Fu H et al. CRAG: de novo characterization of cell-free DNA

fragmentation hotspots in plasma whole-genome sequencing. Genome Med 2022; 14

(1): 138.

20 Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using

multidimensional cell-free DNA fragmentomics. Nat Med 2025.

21   Bogdan B, Hossein A, Mohammad HF, Ashkan A. Novel proteomics-based plasma test

for early detection of multiple cancers in the general population. BMJ Oncology 2024; 3

(1): e000073.

22   Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ

Precis Oncol 2018; 2: 23.

23   Kisiel JB, Ebbert JO, Taylor WR et al. Shifting the Cancer Screening Paradigm:

Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing.

Life 2024; 14 (8): 925.

24   Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers

with a multi-analyte blood test. Science 2018; 359 (6378): 926-930.

25   Douville C, Nobles C, Hwang HJ et al. 73P Multi-cancer early detection through

evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Annals of

Oncology 2022; 33: S575.

26   Gianullin V, Hagmann L, Arvai K et al. Abstract P041: Improved sensitivity of a multi-

analyte early detection test based on mutation, methylation, aneuploidy, and protein

biomarkers. Cancer Prevention Research 2023; 16 (1_Supplement): P041-P041.

27   Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-

CT to screen for cancer and guide intervention. Science 2020; 369 (6499): eabb9601.

28   Putcha G, Liu T-Y, Ariazi E et al. Blood-based detection of early-stage colorectal cancer

using multiomics and machine learning. Journal of Clinical Oncology 2020; 38 (4_suppl):

66-66.

29   Yang Z, LaRiviere MJ, Ko J et al. A Multianalyte Panel Consisting of Extracellular

Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and

Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020; 26 (13): 3248-

3258.

30   Douville C, Cohen JD, Ptak J et al. Assessing aneuploidy with repetitive element

sequencing. Proc Natl Acad Sci U S A 2020; 117 (9): 4858-4863.

31   Allawi HT, Katerov S, Vaccaro A et al. Abstract 631: Validation of a panel of methylated

DNA and protein markers for multi-cancer detection in plasma. Cancer Research 2022;

82 (12_Supplement): 631-631.

32   Katerov VE, Fleming HL, Rugowski DE et al. The detection of multiple cancer types with

an extended set of methylation and protein markers. Journal of Clinical Oncology 2023;

41 (16_suppl): 3040-3040.

33   Katerov S, Vaccaro A, Hennek J et al. Abstract 111: Accurate multi-cancer detection

using methylated DNA markers and proteins in plasma. Cancer Research 2021; 81

(13_Supplement): 111-111.

34   Cohen JD, Douville C, Dudley JC et al. Detection of low-frequency DNA variants by

targeted sequencing of the Watson and Crick strands. Nat Biotechnol 2021; 39 (10):

1220-1227.

35   U.S. Census Bureau 2020. Profile of General Population and Housing

Characteristics.[Accessed may 2,

2025].https://data.census.gov/table?g=010XX00US&d=DEC+Demographic+Profile

36   United States Food and Drug Administration. 2020 Drug Trail Snapshorts.[Accessed

March 9, 2025]. https://www.fda.gov/media/145718/download

37   Brito-Rocha T, Constancio V, Henrique R, Jeronimo C. Shifting the Cancer Screening

Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.

Cells 2023; 12 (6).

38   Dao J, Conway PJ, Subramani B et al. Using cfDNA and ctDNA as Oncologic Markers:

A Path to Clinical Validation. International Journal of Molecular Sciences 2023; 24 (17):

13219.

39   He W, Xiao Y, Yan S et al. Cell-free DNA in the management of prostate cancer: Current

status and future prospective. Asian Journal of Urology 2023; 10 (3): 298-316.

40   American Cancer Society. Cancer Facts & Figures 2025. Atlanta, GA; 2025.[Accessed

March 5, 2025]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-

and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf

Table 1. Participant demographics for classifier development

Variable		Non-Cancer (4914)	Cancer (1438)	Total (6352)
Sex	Female	2799 (57.0%)	776 (54.0%)	3575 (56.3%)
	Male	2115 (43.0%)	662 (46.0%)	2777 (43.7%)
Age (years)	Mean (SD)	65.1 (8.1)	66.9 (9.0)	65.5 (8.3)
	(Min, Max)	(50, 101)	(50, 92)	(50, 101)
Race	American Indian or Alaska Native	20 (0.4%)	9 (0.6%)	29 (0.5%)
	Asian	145 (3.0%)	58 (4.0%)	203 (3.2%)
	Black or African American	698 (14.2%)	119 (8.3%)	817 (12.9%)
	Mixed Race	11 (0.2%)	2 (0.1%)	13 (0.2%)
	Native Hawaiian or Other Pacific Islander	5 (0.1%)	1 (0.1%)	6 (0.1%)
	Unknown/Missing	39 (0.8%)	56 (3.9%)	95 (1.5%)
	White	3996 (81.3%)	1193 (83.0%)	5189 (81.7%)
Ethnicity	Hispanic/Latino	748 (15.2%)	80 (5.6%)	828 (13.0%)
	Not Hispanic/Latino	4135 (84.1%)	1308 (91.0%)	5443 (85.7%)
	Unknown/Missing	31 (0.6%)	50 (3.5%)	81 (1.3%)

Table 2. MP classifier test set performance

	Performance (95% CI)	n/N
Specificity	98.5% (97.9-98.9)	2,397/2,434
Overall Sensitivity, all cancers	50.9% (47.3-54.5)	371/729
Stage I	15.4% (10.9-21.3)	28/182
Stage II	38.0% (30.9-45.7)	62/163
Stage III	67.8% (60.6-74.2)	122/180
Stage IV	85.5% (79.4-90.0)	147/152
Unknown Stage	37.5% (22.9-54.7)	12/32
Stages I/II	26.1% (21.7-31.0)	90/345
Overall Sensitivity, breast and prostate cancers excluded	56.8% (52.8-60.7)	335/590
Stage I	17.2% (12.0-24.2)	25/145
Stage II	48.6% (39.4-57.9)	53/109
Stage III	73.5% (66.0-79.9)	111/151
Stage IV	86.5% (80.2-91.0)	134/155
Unknown Stage	40.0% (24.6-57.7)	12/30
Stages I/II	30.7% (25.4-36.6)	78/254
Overall Sensitivity*	54.8% (50.4-59.2)	268/489
Overall Sensitivity**	63.7% (58.0-69.0)	186/292

MP, methylation-protein.*sensitivity excluding cancer organ types with average-risk standard of care screening (i.e., excluding breast, prostate, cervix, colon and rectum). **sensitivity for the 6 most aggressive cancer organ types with the shortest 5-year survival rate reported by National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) (i.e., pancreas, esophagus, liver, lung and bronchus, stomach, and ovary).

708   Table 3. MP classifier test set sensitivity by organ type and stage

Organ Type	Sensitivity (95% Confidence Interval)				
	Stage I	Stage II	Stage III	Stage IV	Unknown Stage
Lung and Bronchus (n=159)	13% (6.1%, 25.7%) n=46	52.2% (33%, 70.8%) n=23	77.1% (63.5%, 86.7%) n=48	92.3% (79.7%, 97.3%) n=39	100% (43.9%, 100%) n=3
Breast (n=88)	8.3% (2.3%, 25.8%) n=24	30% (16.7%, 47.9%) n=30	47.8% (29.2%, 67%) n=23	88.9% (56.5%, 98%) n=9	0% (0%, 65.8%) n=2
Colon and Rectum (n=88)	15.4% (4.3%, 42.2%) n=13	50% (29%, 71%) n=18	76% (56.6%, 88.5%) n=25	92.6% (76.6%, 97.9%) n=27	40% (11.8%, 76.9%) n=5
Prostate (n=51)	7.7% (1.4%, 33.3%) n=13	0% (0%, 13.8%) n=24	0% (0%, 39%) n=6	62.5% (30.6%, 86.3%) n=8	
Uterus (n=39)	15% (5.2%, 36%) n=20	25% (4.6%, 69.9%) n=4	57.1% (25%, 84.2%) n=7	83.3% (43.6%, 97%) n=6	0% (0%, 65.8%) n=2
Pancreas (n=37)	42.9% (15.8%, 75%) n=7	50% (21.5%, 78.5%) n=8	100% (64.6%, 100%) n=7	92.9% (68.5%, 98.7%) n=14	0% (0%, 79.4%) n=1
Head and Neck (n=36)	40% (16.8%, 68.7%) n=10	40% (11.8%, 76.9%) n=5	54.5% (28%, 78.7%) n=11	80% (49%, 94.3%) n=10	
Kidney (n=32)	O% (0%, 29.9%) n=9	50% (15%, 85%) n=4	25% (4.6%, 69.9%) n=4	81.8% (52.3%, 94.9%) n=11	0% (0%, 49%) n=4
Stomach (n=30)	20% (3.6%, 62.4%) n=5	57.1% (25%, 84.2%) n=7	85.7% (48.7%, 97.4%) n=7	100% (70.1%, 100%) n=0	50% (9.5%, 90.5%) n=2

Bladder and Urinary (n=28)	14.3% (2.6%, 51.3%) n=7	44.4% (18.9%, 73.3%) n=9	75% (30.1%, 95.4%) n=4	66.7% (30%, 90.3%) n=6	50% (9.5%, 90.5%) n=2
Esophagus (n=27)	0% (0%, 39%) n=6	20% (3.6%, 62.4%) n=5	75% (40.9%, 92.9%) n=8	85.7% (48.7%, 97.4%) n=7	100% (20.7%, 100%) n=1
Liver and Bile Duct (n=25)	40% (11.8%, 76.9%) n-5	83.3% (43.6%, 97%) n=6	100% (67.6%, 100%) n=8	100% (56.6%, 100%) n=5	0% (0%, 79.4%) n=1
Anus (n=16)	0% (0%, 79.4%) n=1	62.5% (30.6%, 86.3%) n=8	66.7% (20.8%, 93.9%) n=3	100% (43.9%, 100%) n=3	0% (0%, 79.4%) n=1
Ovary (n=14)	0% (0%, 79.4%) n=1	0% (0%, 79.4%) n=1	85.7% (48.7%, 97.4%) n=7	66.7% (20.8%, 93.9%) n=3	100% (34.2%, 100%) n=2
Vulva (n=13)	0% (0%, 39%) n=6		66.7% (20.8%, 93.9%) n=3	100% (34.2%, 100%) n=2	50% (9.5%, 90.5%) n=2
Cervix Uteri (n=13)	100% (34.2%, 100%) n=2	66.7% (20.8%, 93.9%) n=3	100% (43.9%, 100%) n=3	100% (34.2%, 100%) n=2	33.3% (6.1%, 79.2%) n=3
Thyroid (n=13)	0% (0%, 49%) n=4	0% (0%, 49%) n=4		50% (15%, 85%) n=4	0% (0%, 79.4%) n=1
Small Intestine (n=10)		66.7% (20.8%, 93.9%) n=3	25% (4.6%, 69.9%) n=4	33.3% (6.1%, 79.2%) n=3	
Non-Hodgkin Lymphoma (n=7)	0% (0%, 79.4%) n=1		0% (0%, 65.8%) n=2	50% (15%, 85%) n=4	

Testis (n=2)	50% (9.5%, 90.5%) n=2			
Multiple Myeloma (n=1)		0% (0%, 79.4%) n=1		

709   MP, methylation-protein.

725   Table 4. MP-reflex classifier test set performance

Test Set	Estimate % (95% CI)	n/N
Specificity	98.5% (97.9-98.9)	2,440/2,477
Sensitivity, all cancers	55.2% (51.6-58.8)	412/746
Stage I	19.0% (14.0-25.3)	35/184
Stage II	41.2% (34.0-48.8)	68/165
Stage III	71.9% (65.0-77.9)	133/185
Stage IV	89.4% (84.1-93.1)	161/180
Unknown stage	46.9% (30.9-63.6)	15/32
Stage I, II	29.5% (25.0-34.5)	103/349
Stage I-III	44.2% (40.0-48.4)	236/534
Sensitivity-excluding breast and prostate	61.6% (57.6-65.3)	373/606
Stage I	21.9% (16.0-29.3)	32/146
Stage II	52.7% (43.5-61.8)	58/110
Stage III	75.9% (68.7-81.9)	120/158
Stage IV	90.8% (85.4-94.3)	148/163
Unknown stage	51.7% (34.4-68.6)	15/29
Stage I, II	35.2% (29.6-41.2)	90/256
Stage I-III	50.7% (45.9-55.5)	210/414
Sensitivity*	59.4% (55.1-63.6)	300/505
Sensitivity**	66.9% (61.4-71.9)	206/308

MP, methylation-protein.*sensitivity excluding cancer organ types with average-risk standard of
care screening (i.e., excluding breast, prostate, cervix, colon and rectum). **sensitivity for the 6
most aggressive cancer organ types with the shortest 5-year survival rate reported by National
Cancer Institute Surveillance, Epidemiology, and End Results (SEER) (i.e., pancreas,
esophagus, liver, lung and bronchus, stomach, and ovary).

Figure 1. MP classifier development and test cohorts

MP, methylation-protein. *One sample was excluded for both age and blood processing
reasons.

745   Figure 2. Testing workflow

747   LR, logistic regression; MP, methylation-protein.

749   Figure 3. a) Methylation-Protein and b) Methylation-Protein-reflex classifier schema

751   MP, methylation-protein.

764   Figure 4. MP classifier organ-specific performance at 98.5% specificity*

766   MP, methylation-protein. NHL, Non-Hodgkin Lymphoma. *Multiple Myeloma (n=1) and testicular
767   cancers (n=2) were omitted from the graph due to the small number of cases. The numbers at
768   the base of each bar represent the number of cases.

778   Figure 5. MP-reflex classifier development and test cohorts

780   MP, methylation-protein; QC, quality control.

789   Figure 6. MP and MP-reflex classifier performance comparison (breast and prostate cancers

790   excluded)*

793   MP, methylation-protein.*using MP-reflex test set cohort (746 cancers and 2,477 non-cancers).
794   The absolute change=%MP reflex sensitivity-%MP sensitivity. The relative change=%MP reflex
795   sensitivity-%MP sensitivity/%MP sensitivity.